Singapore has one of the most advanced and innovative infrastructure in the Asia Pacific region. The Singaporean government has identified the biotech industry as a future growth area contributing to the country’s overall development. The government has allocated a substantial budget to fund the industry. This will make the sector to post strong growth. As per our research report “ Asia Pacific Biotechnology Market (2008-2012)”, the biotech industry in Singapore is expected to grow at a CAGR of around 13% during 2010-2012.
Our research has found Singapore's large tax incentives have made it an attractive destination for multi-national corporations, but such incentives may not be sustainable in the longer term. However, the sector will continue to witness strong growth due to several other factors. We have also found that the IPR regime of the country is quite strong and companies are not hesitating in making investments in the sector. This feature differentiates the Singaporean biotech industry from other biotech markets in the Asian countries like India and China.
The report also features and discusses the biotech industries in countries like India, China, Japan, Malaysia and South Korea. It analyzes the country level trends and growth factors driving the overall industry. Besides, the report contains information about emerging market trends growing in line with the industry developments.
“Asia Pacific Biotechnology Market (2008-2012)” gives comprehensive information of the biotech industry in Asia pacific. Thorough evaluation of the current trends and various industry restraints has been done in the report to project an actual and non-biased picture of the industry. Besides, it covers information of various major players present in the market. The report will prove a useful investment guide for investors looking to investment opportunities in the market.
For more information visit: http://www.rncos.com/Report/IM138.htm |
